NASDAQ:VRML - Vermillion Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4750 -0.02 (-4.04 %) (As of 10/23/2018 09:33 AM ET)Previous Close$0.4930Today's Range$0.4750 - $0.475052-Week Range$0.47 - $2.10Volume400 shsAverage Volume91,273 shsMarket Capitalization$35.76 millionP/E RatioN/ADividend YieldN/ABeta1.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. Receive VRML News and Ratings via Email Sign-up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical SymbolNASDAQ:VRML CUSIPN/A Webwww.vermillion.com Phone512-519-0400 Debt Debt-to-Equity Ratio0.11 Current Ratio5.74 Quick Ratio5.70 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.12 million Price / Sales11.46 Cash FlowN/A Price / CashN/A Book Value$0.06 per share Price / Book7.92 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,490,000.00 Net Margins-398.14% Return on Equity-201.03% Return on Assets-117.39% Miscellaneous Employees40 Outstanding Shares75,270,000Market Cap$35.76 million Vermillion (NASDAQ:VRML) Frequently Asked Questions What is Vermillion's stock symbol? Vermillion trades on the NASDAQ under the ticker symbol "VRML." How were Vermillion's earnings last quarter? Vermillion, Inc. (NASDAQ:VRML) released its quarterly earnings data on Thursday, August, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.04). The company earned $0.71 million during the quarter. Vermillion had a negative return on equity of 201.03% and a negative net margin of 398.14%. View Vermillion's Earnings History. When is Vermillion's next earnings date? Vermillion is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Vermillion. What price target have analysts set for VRML? 1 brokers have issued 12 month target prices for Vermillion's shares. Their forecasts range from $2.25 to $2.25. On average, they anticipate Vermillion's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 356.4% from the stock's current price. View Analyst Price Targets for Vermillion. What is the consensus analysts' recommendation for Vermillion? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vermillion in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vermillion. Who are some of Vermillion's key competitors? Some companies that are related to Vermillion include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN). Who are Vermillion's key executives? Vermillion's management team includes the folowing people: Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 57)Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 55)Mr. Chris Goulart, Sr. VP of Commercial OperationsDr. Jean-François Formela, Exec. Officer (Age 61)Mr. Patrick Carpenter, Gen. Mang. of ASPiRA LABS How do I buy shares of Vermillion? Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vermillion's stock price today? One share of VRML stock can currently be purchased for approximately $0.4930. How big of a company is Vermillion? Vermillion has a market capitalization of $35.76 million and generates $3.12 million in revenue each year. Vermillion employs 40 workers across the globe. What is Vermillion's official website? The official website for Vermillion is http://www.vermillion.com. How can I contact Vermillion? Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected] MarketBeat Community Rating for Vermillion (NASDAQ VRML)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 281MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe VRML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/23/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?